Capmatinib drug introduction

Capmatinib is a targeted therapy drug mainly used to treat non-small cell lung cancer (NSCLC). As a new generation of innovative drugs, capmatinib has a specific molecular target, mainly acting on the MET (tyrosine kinase) protein.

In some patients with lung cancer, the MET pathway may be abnormally activated due to gene mutations or overexpression, promoting uncontrolled growth and spread of cancer cells. The unique feature of capmatinib is that it can selectively inhibit the activity of MET kinase, thereby blocking abnormal cell signaling and inhibiting the growth and spread of cancer cells.

Capmatinib is often used in patients with non-small cell lung cancer who have MET gene mutations or MET overexpression, especially those in whom traditional treatments (such as radiotherapy and chemotherapy) are ineffective or intolerable. This makes capmatinib a targeted treatment option, providing a more personalized treatment plan for specific subgroups of patients.

As an oral medication, capmatinib’s convenience allows patients to administer treatment at home while reducing the impact on patients’ quality of life. However, patients still need to be closely monitored while using capmatinib and strictly follow the doctor's medication instructions to ensure the best efficacy of the drug while minimizing potential adverse reactions.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.